Conference on 7th Annual Pain Management

Venue: BSG House, London, UK

Location: London, United Kingdom

Event Date/Time: Oct 18, 2010 End Date/Time: Oct 19, 2010
Report as Spam


Key Speakers
• Theo F. Meert, Senior Research Fellow, Neuroscience, Johnson & Johnson
• Iain Chessell, VP Neuroscience, MedImmune
• Steve England, Associate Research Fellow, Pfizer
• Anne Estrup Olesen, Mech-Sense, Department of Gastroenterology,Aalborg University
• Anastasia Liapi, Director Business Development & New Product Leader CNS & Pain, Astellas

Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID’s drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?

Join us at 7th Annual Pain Management Conference, where our expert panel of speakers, will share insights on ‘first-to-market’ opportunities, pivotal to achieve success in the global pain market across drugs and devices. With a special spotlight on innovations in analgesics, pipeline drugs and clinical breakthrough for chronic pain therapies, the conference will be an unmissable opportunity to maximise your knowledge and network with diverse industry leaders from the pain management sector.

Learn, exchange ideas and acquire knowledge on:

• Maximising the role of opioids in treatment of persistent pain
• Assessing the market dynamics of chronic pain and key pipeline development
• Gaining new insights into migraine pain and the molecular basis of effective therapeutics
• Developing spinal cord stimulation (SCS) for chronic pain of neuropathic
• Evaluating analgesic effect in experimental visceral pain models through translational pain research
• Examining pathophysiology of cancer pain and opioid tolerance
• Understanding the role of voltage-gated sodium channels in neuropathic pain
• Implementing target nerve growth factor (NGF) for pain therapy
• Devising a new methodology to measure quality of recovery from anaesthesia
• Developing a two step approach for treating diabetic neuropathy: eliminating the cause and relieving the symptoms
• Reviewing novel mechanisms for future pain therapies

Who should attend?

Presidents, CEOs, Vice-Presidents, CSOs, Directors, Senior Business Developers, Researchers and Professors in:
• Analgesia
• Pain Therapies/Research
• Neurosciences/ Neuropharmacology/ Neurology
• CNS Clinical Discovery/Nervous System Research
• Arthritis
• Migraine
• Drug Discovery
• Emerging Targets/Lead Optimisation
• Therapeutics and Molecular Profiling
• Pre-Clinical/Clinical R&D
• Genomics/Proteomics/Bioinformatics/Neuroinformatics
• Translational Medicine
• Imaging
• Regulatory Affairs
• Business Development
• Licensing and External Research
• Quality Control/Assurance
• Global Marketing and Medicine